Pacira BioSciences Newsroom

Pacira BioSciences Secures FDA Approval For New Iovera SmartTip to Manage Chronic Low Back Pain

Benzinga11:49 ET

Express News | Pacira Biosciences Receives FDA 510K Clearance for New Iovera° Smarttip to Manage Chronic Low Back Pain via Long-Lasting Medial Branch Nerve Block

ReutersJan 7 08:00 ET

RBC Raises Price Target on Pacira Biosciences to $18 From $16, Keeps Sector Perform Rating

MT NewswiresJan 7 07:49 ET · Ratings

Insider Sale: Chief Medical Officer of $PCRX (PCRX) Sells 879 Shares

Quiver QuantitativeJan 6 18:31 ET

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Pacira BioSciencesJan 2 00:00 ET

VectorY Strengthens Leadership Team With Appointment of Jim Scibetta as New CEO

BusinesswireDec 16, 2024 07:00 ET

Express News | Doma Perpetual: Urges Pacira to Immediately Commence Stock Tender Offer for 10 Mln Shares Using Its Substantial Cash on Hand

ReutersDec 11, 2024 08:06 ET

Express News | Doma Perpetual: Believes Pacira Biosciences' Stock Is "Grossly Undervalued"

ReutersDec 11, 2024 08:06 ET

Express News | Doma Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira Biosciences, Inc.

ReutersDec 11, 2024 08:05 ET

DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.

PR NewswireDec 11, 2024 08:05 ET

Pacira BioSciences (NASDAQ:PCRX) Shareholders Are up 7.2% This Past Week, but Still in the Red Over the Last Three Years

Simply Wall StDec 10, 2024 14:28 ET

Press Release: Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Dow JonesDec 6, 2024 08:00 ET

Express News | Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 6, 2024 08:00 ET

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Pacira BioSciencesDec 6, 2024 00:00 ET

H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $39

Moomoo NewsDec 5, 2024 11:35 ET · Ratings

PCRX Receives New Patent for Lead Pain Drug Exparel in the US

Zacks Dec 4, 2024 11:30 ET

Decoding 6 Analyst Evaluations For Pacira BioSciences

BenzingaDec 4, 2024 07:00 ET

Express News | HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $39 Price Target

BenzingaDec 4, 2024 06:28 ET

Express News | Pacira Biosciences Inc: Awarded New U.S. Patent Covering Exparel Composition; Provides Protection Into 2044

ReutersDec 3, 2024 07:32 ET

US Manufacturing Index Rises To 43, Highest Since 2020

Business TodayNov 16, 2024 02:13 ET